Q-omics provides the consensus-scored FAM184A profile across patient tissues and cancer cell-line models. FAM184A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, FAM184A is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, FAM184A protein abundance shows 29,989 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRP, KIRC, and PDAC as cancer lineages where FAM184A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM184A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM184A survival associations across molecular data types. FAM184A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM184A RNA expression–survival associations across cancer types. High FAM184A expression shows unfavorable associations in KIRP and UCEC, but favorable associations in LUAD, SKCM, PAAD and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for FAM184A RNA expression.
This table summarizes FAM184A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FAM184A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM184A shows lower tumor expression in KIRC, KICH, LUSC, LUAD, KIRP and THCA. The KIRC box plot shows higher FAM184A RNA expression in normal versus tumor tissue (log2 FC = −1.045, t-test p < 0.001).
This table shows molecular features associated with FAM184A in patient tissues and cancer cell lines. In patient samples, FAM184A shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM184A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
